Zhixiang Jintai announced that it achieved operating income of 778 million yuan in the first three quarters, an increase of 274.75% over the previous year; net profit attributable to shareholders of listed companies was a loss of 6.3835 million yuan. The third quarter achieved operating income of 625 million yuan, an increase of 285.23% year on year; net profit attributable to shareholders of listed companies was 310 million yuan, turning a year-on-year loss into a profit. The change in performance was mainly due to the company's confirmation of GR1803 injection license revenue and sales revenue of the first commercial product, Celikizumab injection, during the reporting period compared to the same period last year. The company's Q3 net profit was 310 million, and Q2 net profit was 167 million. Based on this calculation, Q3 net profit turned a month-on-month loss into a profit.

Zhixiang Jintai announced that it achieved operating income of 778 million yuan in the first three quarters, an increase of 274.75% over the previous year; net profit attributable to shareholders of listed companies was a loss of 6.3835 million yuan. The third quarter achieved operating income of 625 million yuan, an increase of 285.23% year on year; net profit attributable to shareholders of listed companies was 310 million yuan, turning a year-on-year loss into a profit. The change in performance was mainly due to the company's confirmation of GR1803 injection license revenue and sales revenue of the first commercial product, Celikizumab injection, during the reporting period compared to the same period last year. The company's Q3 net profit was 310 million, and Q2 net profit was 167 million. Based on this calculation, Q3 net profit turned a month-on-month loss into a profit.